Novo Nordisk, the maker of Ozempic, has announced exciting new data regarding their upcoming weight loss pill. This pill, known as amycretin, has shown promising results in a Phase 1 clinical trial, with participants experiencing up to a 13% reduction in body weight over a 12-week period. The data was presented at the European Association for the Study of Diabetes conference in Madrid.
In the trial, patients taking either one or two 50mg amycretin pills per day saw significant weight loss compared to those on a placebo. Those taking two pills a day experienced a 13% weight loss, while those on one pill saw over a 10% reduction. This data suggests that amycretin may lead to greater and more rapid weight loss compared to Novo’s current blockbuster injection, Wegovy.
The trial also indicated that amycretin has a similar safety profile to Wegovy and Ozempic, with common side effects including mild to moderate gastrointestinal issues like nausea, vomiting, and diarrhea. The pill targets the same GLP-1 hormone as other weight loss and diabetes drugs, as well as stimulating receptors for amylin, a hormone that regulates hunger.
While the results are promising, the study is still in its early stages and has not yet been published in a peer-reviewed journal. Novo Nordisk is continuing to evaluate amycretin, with plans to release more data in 2025. Depending on the results, the company may move forward with a larger Phase 3 trial.
The obesity drug market is rapidly expanding, with analysts predicting it could be worth up to $100 billion by the end of the decade. Novo Nordisk and Eli Lilly currently dominate this sector, but face competition from newer companies like Viking Therapeutics. Both companies are exploring new drugs and formulations, including weight loss pills, to stay ahead in the market.
Novo Nordisk’s stock saw a significant increase following the announcement of the amycretin trial results. The company’s focus on obesity drugs has helped solidify its position as one of Europe’s most valuable companies.
In conclusion, Novo Nordisk’s amycretin weight loss pill shows great promise in early trials, with the potential to outperform existing treatments. As the company continues to develop and evaluate the drug, the future of weight loss treatments looks increasingly exciting.
